ANI PHARMACEUTICALS, INC Interest and Dividend Income, Operating
ANI PHARMACEUTICALS, INC (ANIP) reported Interest and Dividend Income, Operating of $3.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InterestAndDividendIncomeOperating · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for the quarter ending 2026-06-30 was $3.86M, a 38.72% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for the quarter ending 2026-03-31 was $3.78M, a 44.22% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for the quarter ending 2025-12-31 was $3.54M, a 27.30% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for the quarter ending 2025-09-30 was $3.55M, a 17.91% decline year-over-year.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for fiscal 2025 was $12.50M, a 21.99% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for fiscal 2024 was $16.03M, a 84.33% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for fiscal 2023 was $8.69M, a 1785.90% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC interest and dividend income, operating for fiscal 2022 was $461.00K.
| Period end | Interest and Dividend Income, Operating 3 month | Interest and Dividend Income, Operating 6 month | Interest and Dividend Income, Operating 9 month | Interest and Dividend Income, Operating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.86M 10-Q · filed 2026-08-07 | $7.64M 10-Q · filed 2026-08-07 | $11.19M derived: sum of 3 quarters · filed 2026-08-07 | $14.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $3.78M 10-Q · filed 2026-05-08 | $7.33M derived: sum of 2 quarters · filed 2026-05-08 | $10.88M derived: sum of 3 quarters · filed 2026-05-08 | $13.66M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $7.10M derived: sum of 2 quarters · filed 2026-02-27 | $9.88M derived: sum of 3 quarters · filed 2026-08-07 | $12.50M 10-K · filed 2026-02-27 |
| 2025-09-30 | $3.55M 10-Q · filed 2025-11-07 | $6.34M derived: sum of 2 quarters · filed 2026-08-07 | $8.96M 10-Q · filed 2025-11-07 | $11.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $2.78M 10-Q · filed 2026-08-07 | $5.41M 10-Q · filed 2026-08-07 | $8.19M derived: sum of 3 quarters · filed 2026-08-07 | $12.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.62M 10-Q · filed 2026-05-08 | $5.41M derived: sum of 2 quarters · filed 2026-05-08 | $9.73M derived: sum of 3 quarters · filed 2026-05-08 | $14.15M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $7.11M derived: sum of 2 quarters · filed 2026-02-27 | $11.53M derived: sum of 3 quarters · filed 2026-02-27 | $16.03M 10-K · filed 2026-02-27 |
| 2024-09-30 | $4.33M 10-Q · filed 2025-11-07 | $8.74M derived: sum of 2 quarters · filed 2025-11-07 | $13.24M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $4.41M 10-Q · filed 2025-08-08 | $8.92M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $4.50M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $8.69M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $461.00K 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |